Sept 27, 2018

QuiaPEG continues the commercialization of avUni-Qleaver® together with Sinopeg by exhibiting in Sinopeg's booth at the major trade fair CPHI in madrid, 9-11 october.

QuiaPEG pharmaceuticals AB, earlier this year, signed a licensing and commercialization agreement with Chinese, globally active Sinopeg Biotech Ltd (“Sinopeg”) for the development, manufacture, marketing and sales of products and services based on QuiaPEG’s releasable pegylation technology, avUni-Qleaver®. The trade fair CPHI in madrid will have more than 45,000 visitors representing the pharmaceutical industry in more than 150 different countries.
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message